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Background: Intermittent ICS treatment with SABA in response to symptoms, is an emerging
strategy for control of mild-to-moderate asthma, and recurrent wheezing. This systematic
revue compares the efficacy of daily vs. intermittent ICS among preschoolers, children and
adults with persistent wheezing and mild to moderate stable persistent asthma.
Methods: Systematic review of randomized, placebo-controlled trials with a minimum of 8
weeks of daily (daily ICS with rescue SABA during exacerbations) vs. intermittent ICS (ICS plus
SABA at the onset of symptoms), were retrieved through different databases. Primary outcome
was asthma exacerbations; secondary outcomes were pulmonary function tests, symptoms,
days without symptoms, SABA use, corticosteroids use, days without rescue medication use,
expired nitric oxide and serious adverse events.
Results: Seven trials (1367 participants) met inclusion criteria there was no statistically signif-
icant difference in the rate of asthma exacerbations between those with daily vs. intermittent
ICS (0.96; 95% CI: 0.86, 1.06, I2 Z 0%). In the sub-group analysis, no differences were seen in
duration of studies, step-up strategy or age. However, compared to intermittent ICS, the daily
ICS group had a significant increase in asthma-free days and non-significant decreases in rescue
SABA use and exhaled nitric oxide measurement.index; CI, confidence interval; FEV1, forced volume in the first second; HR, hazard ratio; ICS, inhaled
; PEF, peak expiratory flow; RR, risk ratio; SABA, short-acting beta2-agonists; SAE, serious adverse
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1134 G.J. Rodrigo, J.A. Castro-Rodrı´guezConclusions: No significant differences between daily and intermittent ICS in reducing the inci-
dence of asthma exacerbations was found. However, the daily ICS strategy was superior in
many secondary outcomes. Therefore, this study suggests to not change daily for intermittent
ICS use among preschoolers, children with persistent wheezing and adults with mild-to-
moderate stable persistent asthma. International prospective register of systematic reviews
http://www.crd.york.ac.uk/PROSPERO/ (CRD42012003228).
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Current guidelines for chronic asthma management recom-
mend the use of daily inhaled corticosteroids (ICS) as
preferred treatment for preschoolers, children, adolescents
and adults with recurrent wheezing and mild-to-moderate
persistent asthma (mainly GINA 2 level).1e3 In addition, they
should use fast-acting rescue medications to relieve acute
symptoms. This recommendation has been supported by
studies reporting that such treatment improves physiolog-
ical measures of airway obstruction, severity of symptoms,
frequency of exacerbations and quality of life,4,5 and has
been reinforced by reports that continuous ICS treatment
should prevent progressive loss of pulmonary function.6,7
However, intermittent or as-needed ICS treatment with
short-acting beta2 agonists (SABA) in response to symp-
toms, is an emerging strategy for control of mild-to-
moderate persistent asthma,8 and recurrent wheezing.9
Basing treatment on symptoms could reduce the amount
of drug used, minimize the risk of adverse events, and
reduce health care costs. Furthermore, ICS may rapidly
exert their anti-inflammatory effects,10 enhance the effect
of beta2-agonists, and be as effective as systemic cortico-
steroids in treating asthma exacerbations. In particular,
concerns about growth retardation, parental resistance,
and patient adherence to a daily regimen of ICS promoted
this new strategy.11 Contrary, physicians prescribing inter-
mittent ICS would give the wrong message to their patients
about the chronicity of the disease. Thus, at present, we
are seeing a significant controversy.12,13
Only one systematic review has been published on this
topic.14 The search of literature was conducted until
December 2011, and authors included six studies with seven
comparisons, with two different contrasts from the same
trial.15 However, according with the inclusion criteria, one of
them should not be included. Therefore, it seems reasonable
to perform a new systematic review was to compare the ef-
ficacy and safety profile of daily vs. intermittent ICS in the
management of preschoolers, children and adults with
persistent wheezing and mild-to-moderate stable persistent
asthma. Two specific questions were identified: 1) Does
intermittent therapy with ICS provides significant clinical
benefits compared with daily ICS; and 2)What are the risks of
daily use of ICS comparedwith the intermittent-use strategy?
Methods
We adopted Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) guidelines to perform
this systematic review.16Search and selection criteria
We identified published studies from MEDLINE, EMBASE,
CINAHL, SCOPUS and the Cochrane Controlled Trials
Register (CENTRAL) (April 2013) database using the terms
“intermittent” or “as-needed’ or “prn” or “irregular” or
“sporadic” or “short-course” or “daily” or “regular” or
“continuous” and “asthma”. Trials published solely in ab-
stract form were excluded because the methods and results
could not be fully analyzed.
To be included, studies had to meet all the following
criteria: a) randomized (only parallel group) controlled
trials without language restriction of more than 8 weeks of
duration; b) inclusion of children (18 years) and adults
with recurrent wheezing or mild to moderate persistent
asthma; c) comparison of intermittent or as-needed
(intermittent administration of ICS at the onset of exacer-
bations in combination with rescue SABA) vs. continuous ICS
(daily ICS with rescue SABA during exacerbations); long-
acting beta2-agonists were excluded as a part of treat-
ment; and d) report at least one of the following outcomes:
asthma exacerbations as a primary variable; and pulmonary
function tests, symptoms, days without symptoms, SABA
use, corticosteroids use, days without rescue medications
use, biological markers (eosinophil count in sputum,
expired nitric oxide, etc.), withdrawals (total, and due to
treatment failure), and serious adverse events (SAE) as
secondary variables. A SAE was defined as any untoward
medical occurrence that sometimes results in death, is life-
threatening, requires inpatient hospitalization, or results in
persistent or significant disability/incapacity.17Data extraction and assessment of risk of bias
Titles, abstracts, and citations were independently
analyzed by the two authors (GJR and JCR). From the full
text, they independently assessed all studies for inclusion
based on the criteria for population intervention, study
design, and outcomes. After obtaining full reports about
potentially relevant trials, they assessed eligibility. Both
authors were independently involved in all stages of study
selection, data extraction, and risk of bias assessment. The
latter was assessed according to recommendations outlined
in the Cochrane Handbook18 for the following items: 1) ad-
equacy of sequence generation; 2) allocation concealment;
3) blinding of participants and investigators; 4) blinding of
outcome assessment; 5) incomplete outcome data; 6) se-
lective outcome reporting, and other bias. Each potential
source of bias was graded as high, low or unclear risk of bias.
Disagreements were discussed and resolved by consensus.
Figure 1 Flowchart for identification of studies used.
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Analysis was by intention to treat and included all partici-
pants to minimize bias. Outcomes were pooled using mean
differences (MDs) (inverse variance method) or Mantel-
Haenszel risk ratios (RRs) or hazard ratios (HRs). When ef-
fect estimates were significantly different between groups,
the number needed to treat for benefit (NNTB) or for harm
(NNTH) was obtained. Heterogeneity was measured by the
I2 test19 (25% absence, 26e39% unimportant, 40%e60%
moderate, and 60%e100% substantial). Because selected
studies differed in the mixes of participants and in-
terventions, a random-effects model was performed to
address this variation across studies for all outcomes.20 As a
priori subgroup analysis, we explored the influence of age
(children vs. adults), trial duration (<54 vs. 54 weeks) and
step-up ICS strategy (equivalent ICS dose in both groups vs.
a higher ICS dose in the intermittent group compared to the
daily group). Subgroups were compared using the residual
Chi2 test from the Peto odds ratios.21 Potential publication
bias was analyzed through the use of a funnel plot and the
Egger test.22 Inter-observer agreement for full text study
selection was measured using kappa statistic. P  0.05
(2-tailed test) was considered significant except for the
Egger test (P < 0.1, and 90% CI). Meta-analysis was per-
formed with the Review Manager 5.2.3 software (Cochrane
IMS, 2013).
Results
The process of study selection is outlined in Fig. 1.
Reviewer agreement at the level of study selection from
full text articles as assessed by kappa statistic was 0.87
(standard error 0.14). Seven trials8,9,15,23e26 (1367 patients,
65 years) met the entry criteria. All studies were
randomized, parallel group, placebo-controlled, and
three9,23,24 were sponsored by a single pharmaceutical
company. Two studies included preschoolers,24,25 two
children,9,15 and three adults8,23,26 (Table 1). Most studies
included children and adults with mild asthma controlled
with low doses of ICS.8,9,15,23,26 The remaining two studies
include preschoolers with a positive asthma predictive
index (API)27 in the first study, and a positive or negative
index in the second.24 In three studies,9,23,26 the daily ICS
dose was stepped-up to the same dose used in the inter-
mittent group. In contrast, four trials8,15,24,25 compared
daily dose to a higher ICS dose in the intermittent group.
Beclomethasone or budesonide (160e2000 mg/day) was
increased stepwise in the intermittent group for 7e14 days.
All studies showed a high adherence to treatment (75%e
95%). Overall, the majority of studies were judged to have a
low risk of bias (Table 2).
Primary outcome
Data from five studies8,15,23e25 showed no statistically sig-
nificant difference in the frequency of asthma exacerba-
tions among patients receiving daily ICS and those receiving
intermittent ICS (RR Z 0.96; 95% CI, 0.86, 1.06, p Z 0.40,
I2 Z 0%) (Fig. 2A). There was no evidence of publication
bias (Egger’s test, Intercept Z 0.05; 90% CI: 0.31 to0.68, pZ 0.68) or significant heterogeneity among studies.
In the same way, compared with daily use of ICS, inter-
mittent use of ICS did not significantly decrease the number
of patients with one or more exacerbations requiring oral
corticosteroids (Fig. 2B). Finally, the pooled analysis did not
show a significant difference between groups regarding the
time to exacerbation requiring oral corticosteroids, or
asthma exacerbations in terms of events/person-year
(Table 3). Post hoc subgroup analysis showed no signifi-
cant differences in terms of age, (RR Z 1.23; 95% CI: 0.75,
2.03, pZ 0.4), duration of studies (RRZ 1.4; 95% CI: 0.79,
1.60, p Z 0.46), or step-up strategy (RR Z 1.01; 95% CI:
0.62, 1.63, p Z 0.96). Sensitivity analysis was not done
because the absence of heterogeneity and the high quality
of studies.
Secondary outcomes
Compared to intermittent ICS, the daily ICS group displayed
a significant increase in percent asthma-free days
(RR Z 1.10%; 95% CI: 1.01, 1.20) (Fig. 3A), as well as non-
significant decreases in rescue b2-agonists use (Fig. 3B)
and exhaled nitric oxide (Table 3). As was expected, the
Table 1 Characteristics of included studies.a
Study Location
and
duration,
weeks
Randomized
patients,
n (% female)
Mean age,
(range)
Eligibility criteria Primary outcome Selected comparisons
Daily ICS Intermittent ICS
Between
exacerbations
During exacerbations
Boushey8 Multic 54 149 (62) 33y (18e65) Physician-diagnosed
mild persistent
asthma PEF
reversibility
Morning PEF BUD 200 mg TD BUD 200 mg
TD þ ALB prn
BUD 400 mg TD for 10 days or
PRED 0.5 mg/kg per day for
5days þ ALB prn
Papi23 Multic 26 234 (58) 37y (18e65 Mild persistent
asthma PEF
reversibility,
Morning PEF BDP 250 mg TD BDP 250 mg TD þ
ALB 100 mg prn
BDP 250 mg þ ALB 100 mg prn
Turpeinen9 Single-
centre 54
116 (38) 6.9y (5e10) Interim symptoms
PEF reversibility
(mild asthma)
Morning PEF BUD100 mg TD BUD 400 mg TD
for 2 weeks þ
TERB 0.25 mg/
dose prn
BUD 400 mg TD þ TERB 0.25 mg/
dose for 2 weeks prn
Papi24 Multic 12 220 (34) 2.3y (1e4) Frequent
wheezing. API
positive or
negative
Symptom free days BDP 400 mg NEB TD BDP 400 mg NEB
TD þ ALB 2500 mg prn
BDP 800 mg þ ALB 1600 mg prn
Martinez15 Multic 44 143 (45) 10.6y (6e18) Well controlled
mild persistent
asthma on low
dose ICS
Time to first
exacerbation.
BDP 40 mg TD BDP 40 mg TD þ
ALB prn
BDP 80 mg whenever taking
2 puffs of ALB 180 mg prn
Zeiger25 Multic 54 278 (31) 12e53 m (NA) Recurrent
wheezing with
API positive
values, high-risk
asthma and low
impairment
Exacerbations BUD 0.5 mg NEB OD BUD 0.5 mg NEB
OD þ ALB 180 mg
per MDI or 2.5 mg
NEB prn
BUD 1 mg NEB TD for 7days þ
ALB 180 mg MDI or 2.5 mg NEB
Calhoun26 Multic 36 w 227 (68) 33y (NA) Mild to moderate
asthma controlled
by low-dose ICS
Time to first
treatment failure
BDP 80 mg TD
adjusted every
6 w according to
guidelines
BDP 80 mg TD
adjusted according
to guidelines þ
ALB prn
BDP (80 mg) whenever taking
2 puffs of ALB
a ALB Z albuterol; API Z Asthma predictive index; BDP Z beclomethasone; BUD Z budesonide; ICS Z inhaled corticosteroids;
MDI Z meter-dose inhaler; Multic Z Multicenter; NA Z no data available; NEB Z nebulized; PEF Z peak expiratory flow;
PRED Z prednisone; OD Z once daily; TERB Z terbutaline; TD Z twice daily.
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Table 2 Risk of bias of eligible studies.
Study Adequate
sequence
generation
Allocation
concealment
Blinding of
participants
and personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective reporting
and other sources
of bias
Boushey8 Low Low Low Unclear Low Low
Papi23 Low Low Low Low Low Low
Turpeinen9 Low Unclear Low Low Low Low
Papi24 Low Low Low Low Low Low
Martinez15 Low Low Low Low Low Low
Zeiger25 Low Low Low Low Unclear Low
Calhoun26 Low Low Low Low Low Low
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8.67 mg/monthly less with the intermittent regimen than
with the daily regimen (Table 3). One study8 reported that
patients should be treated with daily ICS showing greater
improvements in percentage of eosinophils in sputum
(MD Z 0.50%; 95% CI: 0.45, 0.55, p Z 0.0001). There were
no group differences in pulmonary tests, total withdrawals,
withdrawals due to treatment failure, and SAE (Table 3).
Finally, pediatric studies did not show significant difference
in linear growth rate (MDZ 0.35 cm/y; 95% CI: 0.08, 0.78)
between groups (Table 3).
Discussion
International guidelines recommend the use of ICS twice
daily for people with wheezing and mild-to-moderateFigure 2 Pooled relative risk for asma exacerbations with 95%
intermittent ICS use. Rate of exacerbations (Panel A) and numbe
corticosteroids (Panel B).persistent asthma to control their condition.1e3 In addi-
tion, patients should use rescue medications when needed
to relieve symptoms. However, the daily use of ICS even
when people feel fine is very problematic. Thus, many
patients tend to take the medication until they become
asymptomatic. This pattern of poor adherence to daily use
of ICS28 has led to the hypothesis that linking ICS-use to the
intermittent use of a short-acting bronchodilator can
improve asthma control, focusing ICS therapy on periods
when symptoms are more evident. Additionally, this
intermittent-use strategy could potentially reduce costs
and adverse events of long-term regular therapy. Thus, the
practice of prescribing ICS intermittently was established
over a decade ago, although until recently without
supporting evidence. It has recently been suggested
that as-needed ICS could also be an alternative step-2confidence intervals of eligible studies comparing daily vs.
r of patients with one or more exacerbations requiring oral
Table 3 Effect of daily vs. intermittent use of ICS on different asthma outcomes.
Outcome Studies n Estimate Effect (95% CI) I2 % (p)
Time to exacerbation requiring oral corticosteroids. 15, 25e26 648 HR 1.08 (0.52,2,24) 84 (0.83)
Exacerbations/person-year 23,25e26 733 MD 0.00 (0.12, 0.13) 0 (0.97)
Mean change exhaled nitric oxide (%). 8,15,26 499 MD 28.57 (62.29, 5.14) 59 (0.10)
Cumulative dose of Beclomethasone or equivalent
(mg/monthly).
23e26 959 MD 8.67 (15.35, 1.98) 96 (0.001)
Mean change pre-bronchodilator FEV1 (%) 8,15,23,26 851 MD 0.89 (2.90, 1.12) 78 (0.39)
Total withdrawals 8,15,23e26 1367 RR 0.93 (0.68, 1.27) 20 (0.65)
Serious adverse events 8e9,15,23e26 1367 RR 0.96 (0.71, 1.30) 0 (0.79)
Withdrawals due to treatment failure 9,15,23,25 771 RR 0.66 (0.23, 1.89) 37 (0.44)
Linear growth rate (cm/y) 9,15,25 537 MD 0.35 (0.08, 0.78) 0 (0.11)
FEV1 Z forced expiratory volume in the first second; HR Z hazard ratio; MD Z mean difference; n Z number of subjects; RR Z risk
ratio.
1138 G.J. Rodrigo, J.A. Castro-Rodrı´gueztherapeutic approach for mild persistent asthma and even
for individuals who have not previously received a course of
daily corticosteroid treatment.15
In the present study, the more extensive systematic re-
view performed exclusively to evaluate the efficacy and
safety of intermittent use of ICS compared with daily use in
patients with recurrent wheezing and mild to moderate
persistent asthma, we did not found significant differences
between the two strategies in terms of asthma exacerba-
tions (primary outcome) and pulmonary function tests.
Concerning the benefits (first question), daily ICS therapy
showed a 10% increase in asthma-free days compared with
intermittent-use strategy. Also, daily ICS use was associ-
ated with a non-significant decrease in rescue SABA use.Figure 3 Pooled relative risk for percent asthma free days (Pane
(Panel B) with 95% confidence intervals of eligible studies compariHowever it is difficult to establish the clinical importance of
this significant difference. Minimal clinical important dif-
ferences have rarely been reported for symptom scores,
with most papers merely reporting statistically significant
changes in mean scores.29
About the risks (second question), the daily regimen was
associated with greater exposure to ICS. However, there
were no significant differences in the rate of total with-
drawals, withdrawals due to treatment failure, and SAE.
Data from pediatric studies showed a small decline in the
short-term linear growth rate during treatment with daily
ICS but this effect was not significant. However, this data
must be analyzed in light of the fact that the impact on
growth is dose dependent. Thus, it is critical to use thel A) or mean difference for mean change in rescue medication
ng daily vs. Intermittent ICS use.
Daily vs. intermittent inhaled corticosteroids for recurrent wheezing and mild persistent asthma 1139smallest effective dose of ICS (and new safety molecules)
and to gradually reduce its use in accordance with clinical
follow-up examinations, which was not done in any of the
trials included in the present meta-analysis. A recent study
reported an initial decrease in attained height associated
with the use of ICS (636.1 mg/day of budesonide) in pre-
pubertal children that persisted as a reduction in adult
height (1.2 cm), although the decrease was not progressive
or cumulative.30 Finally, of particular concern is the
increasing exhaled nitric oxide and eosinophils in sputum
associated with the intermittent ICS therapy. More studies
are needed evaluating biomarkers and airway remodeling
between these two strategies to clarify this issue.
Overall, the results of our systematic review are
consistent with those of a previous one.14 However, both
reviews have two important differences. Firstly, Chauhan
et al. pooled data from six studies with seven comparisons;
authors included two different comparisons from the same
trial15; however, one of them was excluded in our study
according with inclusion criteria (the daily group used ICS
plus SABA as rescue medication instead SABA alone). On the
other hand, our review included a new trial published in
2012. Together, these differences represent a change of
28% in the sample size between the two studies. Accord-
ingly, this difference may be important due to the small
number of studies included, and increases confidence in the
results of our review.
This review was performed according to the methodo-
logical criteria suggested for scientific guidelines.16 Trial
qualities were formally assessed, and the results were
clearly reported; overall, the quality of the studies was
high, and there was no evidence of publication bias. In-
clusion criteria were clearly defined. Different relevant
databases were searched for published and unpublished
articles in any language. The effect sizes were consistent
and the pooled results of primary outcomes showed ho-
mogeneity. Subgroup and sensitivity analysis did not modify
the main outcome size effect. However, the small number
of trials included can be considered a limitation of this
review. As well, the results can be limited by the diversity
of the studies related to disease characteristics (wheezing
or intermittent or persistent mild asthma).
Does current evidence support a change in the direc-
tion of the use of an intermittent-use strategy for recur-
rent wheezing and mild to moderate persistent asthma?
This review suggests a negative answer. Even, some data
suggest a slight superiority of the daily-use strategy on the
intermittent-use strategy (asthma-free days, rescue
medication use, and inflammatory markers). Therefore, at
this point, there is no convincing basis to alter the
current approach to ICS dosing for mild or mild-to-
moderate persistent asthma and more studies are
needed comparing these two strategies. While taking in
consideration the superiority of daily ICS over intermit-
tent ICS in terms of secondary outcomes, we need to
improve patient compliance with daily ICS in order to
make asthma control more effective. We should not give
up on educating our patients about the favorable risk/
benefit balance of daily low-dose ICS simply because it is
time-consuming. Instead, we should remember that when
recommending intermittent therapy, we are telling our
patients that asthma is not a chronic disease, only arecurrent one; so let us be sure, we have classified the
phenotype and severity correctly.
In conclusion, this systematic review does not support a
change in current guidelines for treatment of recurrent
wheezing and mild-to-moderate persistent asthma.
Currently, daily ICS is the preferred therapeutic approach.
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